Blackrock, INC Schedule 13G passive stakes
NYSE
SCHEDULE 13G/A: BlackRock Reduces Stake in Aura Biosciences to 4.9%
BlackRock, Inc. has filed an amended Schedule 13G, reporting a reduction in its beneficial ownership stake in Aura Biosciences Inc. to 4.9% of common stock.
NYSE
SCHEDULE 13G/A: BlackRock Amends Passive Stake in Biomea Fusion to 1.3%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.3% passive beneficial ownership stake in Biomea Fusion, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 2.0% Stake in Blink Charging Co.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.0% beneficial ownership stake in Blink Charging Co. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.8% Passive Stake in Bumble Inc.
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive ownership stake in Bumble Inc.'s common stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.9% Passive Stake in CVR Energy Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.9% passive beneficial ownership stake in CVR Energy Inc. as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% beneficial ownership stake in ChargePoint Holdings Inc. Class A Stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.6% Passive Stake in Compass Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.6% beneficial ownership stake in Compass Therapeutics, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.7% Stake in ConocoPhillips
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in ConocoPhillips common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.5% beneficial ownership stake in Contango Ore Inc.'s common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 2.9% Passive Stake in Corbus Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in Corbus Pharmaceuticals Holdings Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.6% Stake in 1-800-FLOWERS.COM
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in 1-800-FLOWERS.COM, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Semler Scientific Stake Disclosure to 4.3%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.3% beneficial ownership stake in Semler Scientific Inc. common stock.
NYSE
SCHEDULE 13G/A: BlackRock Amends SoundThinking Stake, Reports 4.9% Ownership
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in SoundThinking, Inc. as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in American Vanguard Corporation's common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has reported a 7.8% beneficial ownership stake in Core Scientific, Inc., holding over 23 million shares of common stock.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Fidelity D&D Bancorp Inc. common stock, held for passive investment purposes.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.0% Stake in UROGEN PHARMA LTD
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.0% in UROGEN PHARMA LTD's common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.7% Passive Stake in Amcor PLC
BlackRock, Inc. has filed an updated Schedule 13G, revealing a 6.7% beneficial ownership in global packaging leader Amcor PLC, held for passive investment purposes.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in WNS Holdings Ltd, held passively.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.3% Passive Stake in Assurant, Inc.
BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 6.3% of Assurant, Inc.'s common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 1.6% Passive Stake in Atossa Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.6% beneficial ownership stake in Atossa Therapeutics, Inc.'s common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 7.7% beneficial ownership stake in Centene Corporation as of June 30, 2025.
NYSE
BlackRock, Inc. has disclosed a beneficial ownership of 7.3% of Seadrill Ltd's common stock, totaling 4,542,737 shares.
NYSE
BlackRock, Inc. has filed an updated Schedule 13G, reporting a 5.1% beneficial ownership stake in Ultrapar Holdings Inc. as a passive investor.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a passive ownership of 1.8% of UR Energy Inc.'s common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.1% beneficial ownership stake in Vermilion Energy Inc. as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.1% beneficial ownership stake in AngloGold Ashanti PLC's common stock, held for ordinary business purposes.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Burford Capital Ltd's common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 6.5% of ABSCI CORP's common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.0% beneficial ownership stake in BIO-TECHNE Corporation's common stock as of June 30, 2025.